nodes	percent_of_prediction	percent_of_DWPC	metapath
Gefitinib—ABCG2—Leflunomide—systemic scleroderma	0.0948	0.168	CbGbCtD
Gefitinib—ABCG2—Mycophenolate mofetil—systemic scleroderma	0.0585	0.104	CbGbCtD
Gefitinib—ALB—Captopril—systemic scleroderma	0.0513	0.0911	CbGbCtD
Gefitinib—ALB—Mycophenolate mofetil—systemic scleroderma	0.0404	0.0717	CbGbCtD
Gefitinib—ABCB1—Lisinopril—systemic scleroderma	0.0358	0.0637	CbGbCtD
Gefitinib—CYP2C9—Leflunomide—systemic scleroderma	0.0352	0.0626	CbGbCtD
Gefitinib—CYP3A5—Mycophenolate mofetil—systemic scleroderma	0.0324	0.0577	CbGbCtD
Gefitinib—ALB—Prednisone—systemic scleroderma	0.0323	0.0574	CbGbCtD
Gefitinib—ABCB1—Captopril—systemic scleroderma	0.0268	0.0477	CbGbCtD
Gefitinib—CYP2D6—Captopril—systemic scleroderma	0.0253	0.0449	CbGbCtD
Gefitinib—ABCG2—Methotrexate—systemic scleroderma	0.0235	0.0417	CbGbCtD
Gefitinib—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0211	0.0375	CbGbCtD
Gefitinib—CYP2C19—Prednisone—systemic scleroderma	0.0209	0.0372	CbGbCtD
Gefitinib—ABCB1—Prednisone—systemic scleroderma	0.0169	0.03	CbGbCtD
Gefitinib—ALB—Methotrexate—systemic scleroderma	0.0162	0.0288	CbGbCtD
Gefitinib—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0126	0.0225	CbGbCtD
Gefitinib—CYP2C9—cardial valve—systemic scleroderma	0.0111	0.17	CbGeAlD
Gefitinib—CYP3A4—Prednisone—systemic scleroderma	0.0101	0.018	CbGbCtD
Gefitinib—ABCB1—Methotrexate—systemic scleroderma	0.00847	0.0151	CbGbCtD
Gefitinib—Afatinib—BLK—systemic scleroderma	0.00383	0.351	CrCbGaD
Gefitinib—Bosutinib—CSK—systemic scleroderma	0.00363	0.333	CrCbGaD
Gefitinib—SBK1—tendon—systemic scleroderma	0.00279	0.0428	CbGeAlD
Gefitinib—CHEK2—tendon—systemic scleroderma	0.00243	0.0373	CbGeAlD
Gefitinib—ERBB3—connective tissue—systemic scleroderma	0.00216	0.0332	CbGeAlD
Gefitinib—CHEK2—lung—systemic scleroderma	0.00213	0.0327	CbGeAlD
Gefitinib—MKNK2—connective tissue—systemic scleroderma	0.00206	0.0316	CbGeAlD
Gefitinib—CSNK1E—skin of body—systemic scleroderma	0.00202	0.0311	CbGeAlD
Gefitinib—ERBB3—skin of body—systemic scleroderma	0.00195	0.03	CbGeAlD
Gefitinib—MKNK2—smooth muscle tissue—systemic scleroderma	0.00188	0.0289	CbGeAlD
Gefitinib—IRAK1—smooth muscle tissue—systemic scleroderma	0.00188	0.0289	CbGeAlD
Gefitinib—Vandetanib—BLK—systemic scleroderma	0.00178	0.163	CrCbGaD
Gefitinib—MAP3K19—lung—systemic scleroderma	0.00174	0.0267	CbGeAlD
Gefitinib—Bosutinib—BLK—systemic scleroderma	0.00167	0.153	CrCbGaD
Gefitinib—CSNK1E—digestive system—systemic scleroderma	0.00162	0.0249	CbGeAlD
Gefitinib—ERBB3—digestive system—systemic scleroderma	0.00156	0.024	CbGeAlD
Gefitinib—CSNK1E—tendon—systemic scleroderma	0.00154	0.0237	CbGeAlD
Gefitinib—IRAK4—tendon—systemic scleroderma	0.00152	0.0233	CbGeAlD
Gefitinib—MKNK2—digestive system—systemic scleroderma	0.00148	0.0228	CbGeAlD
Gefitinib—MKNK1—digestive system—systemic scleroderma	0.00147	0.0225	CbGeAlD
Gefitinib—MKNK2—tendon—systemic scleroderma	0.00141	0.0217	CbGeAlD
Gefitinib—IRAK1—tendon—systemic scleroderma	0.00141	0.0217	CbGeAlD
Gefitinib—EGFR—lung—systemic scleroderma	0.00141	0.0216	CbGeAlD
Gefitinib—CSNK1E—lung—systemic scleroderma	0.00135	0.0208	CbGeAlD
Gefitinib—IRAK4—lung—systemic scleroderma	0.00133	0.0204	CbGeAlD
Gefitinib—ERBB3—lung—systemic scleroderma	0.0013	0.02	CbGeAlD
Gefitinib—MKNK2—lung—systemic scleroderma	0.00124	0.019	CbGeAlD
Gefitinib—IRAK1—lung—systemic scleroderma	0.00124	0.019	CbGeAlD
Gefitinib—MKNK1—lung—systemic scleroderma	0.00122	0.0188	CbGeAlD
Gefitinib—STK10—digestive system—systemic scleroderma	0.00121	0.0185	CbGeAlD
Gefitinib—STK10—tendon—systemic scleroderma	0.00115	0.0176	CbGeAlD
Gefitinib—MAP2K5—tendon—systemic scleroderma	0.00103	0.0158	CbGeAlD
Gefitinib—STK10—lung—systemic scleroderma	0.00101	0.0155	CbGeAlD
Gefitinib—CSNK1E—Betamethasone—Mometasone—systemic scleroderma	0.000929	0.228	CbGdCrCtD
Gefitinib—CSNK1E—Dexamethasone—Mometasone—systemic scleroderma	0.000929	0.228	CbGdCrCtD
Gefitinib—MAP2K5—lung—systemic scleroderma	0.0009	0.0138	CbGeAlD
Gefitinib—CSNK1E—Danazol—Prednisone—systemic scleroderma	0.000794	0.195	CbGdCrCtD
Gefitinib—ORM1—lung—systemic scleroderma	0.000731	0.0112	CbGeAlD
Gefitinib—ABCB1—blood vessel—systemic scleroderma	0.000698	0.0107	CbGeAlD
Gefitinib—CYP1A1—skin of body—systemic scleroderma	0.000622	0.00956	CbGeAlD
Gefitinib—CYP2C19—digestive system—systemic scleroderma	0.000618	0.00949	CbGeAlD
Gefitinib—CSNK1E—Betamethasone—Prednisone—systemic scleroderma	0.000507	0.124	CbGdCrCtD
Gefitinib—CSNK1E—Dexamethasone—Prednisone—systemic scleroderma	0.000507	0.124	CbGdCrCtD
Gefitinib—CYP1A1—digestive system—systemic scleroderma	0.000498	0.00765	CbGeAlD
Gefitinib—CYP3A5—digestive system—systemic scleroderma	0.000487	0.00748	CbGeAlD
Gefitinib—CYP2C9—digestive system—systemic scleroderma	0.000479	0.00736	CbGeAlD
Gefitinib—ABCG2—lung—systemic scleroderma	0.000438	0.00673	CbGeAlD
Gefitinib—CYP1A1—lung—systemic scleroderma	0.000416	0.00639	CbGeAlD
Gefitinib—CYP3A5—lung—systemic scleroderma	0.000407	0.00625	CbGeAlD
Gefitinib—CHEK2—Danazol—Prednisone—systemic scleroderma	0.000406	0.0998	CbGdCrCtD
Gefitinib—CYP3A4—digestive system—systemic scleroderma	0.000365	0.00561	CbGeAlD
Gefitinib—CYP2D6—digestive system—systemic scleroderma	0.00036	0.00552	CbGeAlD
Gefitinib—Malaise—Mycophenolic acid—systemic scleroderma	0.000344	0.00136	CcSEcCtD
Gefitinib—Malnutrition—Lisinopril—systemic scleroderma	0.000343	0.00136	CcSEcCtD
Gefitinib—Infection—Azathioprine—systemic scleroderma	0.000343	0.00136	CcSEcCtD
Gefitinib—Urinary tract disorder—Mycophenolate mofetil—systemic scleroderma	0.000341	0.00135	CcSEcCtD
Gefitinib—Fatigue—Captopril—systemic scleroderma	0.000341	0.00135	CcSEcCtD
Gefitinib—Oedema peripheral—Mycophenolate mofetil—systemic scleroderma	0.00034	0.00135	CcSEcCtD
Gefitinib—Urethral disorder—Mycophenolate mofetil—systemic scleroderma	0.000339	0.00134	CcSEcCtD
Gefitinib—Constipation—Captopril—systemic scleroderma	0.000338	0.00134	CcSEcCtD
Gefitinib—Thrombocytopenia—Azathioprine—systemic scleroderma	0.000338	0.00134	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Leflunomide—systemic scleroderma	0.000338	0.00134	CcSEcCtD
Gefitinib—Skin disorder—Azathioprine—systemic scleroderma	0.000335	0.00133	CcSEcCtD
Gefitinib—Dry mouth—Leflunomide—systemic scleroderma	0.000333	0.00132	CcSEcCtD
Gefitinib—Cough—Mycophenolic acid—systemic scleroderma	0.000333	0.00132	CcSEcCtD
Gefitinib—Vomiting—Pentoxifylline—systemic scleroderma	0.000332	0.00131	CcSEcCtD
Gefitinib—Rash—Pentoxifylline—systemic scleroderma	0.000329	0.0013	CcSEcCtD
Gefitinib—Dermatitis—Pentoxifylline—systemic scleroderma	0.000329	0.0013	CcSEcCtD
Gefitinib—Thrombophlebitis—Methotrexate—systemic scleroderma	0.000327	0.00129	CcSEcCtD
Gefitinib—Infection—Leflunomide—systemic scleroderma	0.000324	0.00128	CcSEcCtD
Gefitinib—Gastrointestinal pain—Captopril—systemic scleroderma	0.000324	0.00128	CcSEcCtD
Gefitinib—Asthenia—Mometasone—systemic scleroderma	0.000323	0.00128	CcSEcCtD
Gefitinib—Eye disorder—Mycophenolate mofetil—systemic scleroderma	0.000323	0.00128	CcSEcCtD
Gefitinib—Hypotension—Azathioprine—systemic scleroderma	0.000323	0.00128	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	0.000322	0.00127	CcSEcCtD
Gefitinib—Cardiac disorder—Mycophenolate mofetil—systemic scleroderma	0.000321	0.00127	CcSEcCtD
Gefitinib—Nervous system disorder—Leflunomide—systemic scleroderma	0.00032	0.00126	CcSEcCtD
Gefitinib—Thrombocytopenia—Leflunomide—systemic scleroderma	0.000319	0.00126	CcSEcCtD
Gefitinib—Pruritus—Mometasone—systemic scleroderma	0.000319	0.00126	CcSEcCtD
Gefitinib—Dry mouth—Mycophenolic acid—systemic scleroderma	0.000317	0.00126	CcSEcCtD
Gefitinib—Anaemia—Lisinopril—systemic scleroderma	0.000317	0.00125	CcSEcCtD
Gefitinib—Skin disorder—Leflunomide—systemic scleroderma	0.000317	0.00125	CcSEcCtD
Gefitinib—Hepatic failure—Methotrexate—systemic scleroderma	0.000315	0.00125	CcSEcCtD
Gefitinib—Angioedema—Lisinopril—systemic scleroderma	0.000314	0.00124	CcSEcCtD
Gefitinib—Angiopathy—Mycophenolate mofetil—systemic scleroderma	0.000314	0.00124	CcSEcCtD
Gefitinib—Abdominal pain—Captopril—systemic scleroderma	0.000313	0.00124	CcSEcCtD
Gefitinib—Body temperature increased—Captopril—systemic scleroderma	0.000313	0.00124	CcSEcCtD
Gefitinib—Mediastinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000311	0.00123	CcSEcCtD
Gefitinib—Anorexia—Leflunomide—systemic scleroderma	0.000311	0.00123	CcSEcCtD
Gefitinib—Dry skin—Prednisone—systemic scleroderma	0.00031	0.00123	CcSEcCtD
Gefitinib—Nausea—Pentoxifylline—systemic scleroderma	0.00031	0.00123	CcSEcCtD
Gefitinib—Malaise—Lisinopril—systemic scleroderma	0.00031	0.00122	CcSEcCtD
Gefitinib—Infection—Mycophenolic acid—systemic scleroderma	0.000309	0.00122	CcSEcCtD
Gefitinib—Arrhythmia—Mycophenolate mofetil—systemic scleroderma	0.000309	0.00122	CcSEcCtD
Gefitinib—Diarrhoea—Mometasone—systemic scleroderma	0.000308	0.00122	CcSEcCtD
Gefitinib—Hypokalaemia—Prednisone—systemic scleroderma	0.000308	0.00122	CcSEcCtD
Gefitinib—Shock—Mycophenolic acid—systemic scleroderma	0.000306	0.00121	CcSEcCtD
Gefitinib—Alopecia—Mycophenolate mofetil—systemic scleroderma	0.000305	0.00121	CcSEcCtD
Gefitinib—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.000305	0.00121	CcSEcCtD
Gefitinib—Hypotension—Leflunomide—systemic scleroderma	0.000305	0.0012	CcSEcCtD
Gefitinib—Thrombocytopenia—Mycophenolic acid—systemic scleroderma	0.000305	0.0012	CcSEcCtD
Gefitinib—Skin disorder—Mycophenolic acid—systemic scleroderma	0.000302	0.00119	CcSEcCtD
Gefitinib—Malnutrition—Mycophenolate mofetil—systemic scleroderma	0.000301	0.00119	CcSEcCtD
Gefitinib—Dermatitis exfoliative—Methotrexate—systemic scleroderma	0.0003	0.00119	CcSEcCtD
Gefitinib—Cough—Lisinopril—systemic scleroderma	0.0003	0.00118	CcSEcCtD
Gefitinib—Alanine aminotransferase increased—Prednisone—systemic scleroderma	0.000299	0.00118	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.000298	0.00118	CcSEcCtD
Gefitinib—Anorexia—Mycophenolic acid—systemic scleroderma	0.000297	0.00117	CcSEcCtD
Gefitinib—Dyspnoea—Leflunomide—systemic scleroderma	0.000291	0.00115	CcSEcCtD
Gefitinib—Hypotension—Mycophenolic acid—systemic scleroderma	0.000291	0.00115	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.00029	0.00115	CcSEcCtD
Gefitinib—Pancreatitis—Prednisone—systemic scleroderma	0.000287	0.00113	CcSEcCtD
Gefitinib—Vomiting—Mometasone—systemic scleroderma	0.000286	0.00113	CcSEcCtD
Gefitinib—Dry mouth—Lisinopril—systemic scleroderma	0.000286	0.00113	CcSEcCtD
Gefitinib—Rash—Mometasone—systemic scleroderma	0.000284	0.00112	CcSEcCtD
Gefitinib—Asthenia—Captopril—systemic scleroderma	0.000284	0.00112	CcSEcCtD
Gefitinib—Dermatitis—Mometasone—systemic scleroderma	0.000284	0.00112	CcSEcCtD
Gefitinib—Decreased appetite—Leflunomide—systemic scleroderma	0.000283	0.00112	CcSEcCtD
Gefitinib—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000282	0.00112	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000282	0.00111	CcSEcCtD
Gefitinib—Fatigue—Leflunomide—systemic scleroderma	0.000281	0.00111	CcSEcCtD
Gefitinib—Pruritus—Captopril—systemic scleroderma	0.00028	0.00111	CcSEcCtD
Gefitinib—Pain—Leflunomide—systemic scleroderma	0.000279	0.0011	CcSEcCtD
Gefitinib—Constipation—Leflunomide—systemic scleroderma	0.000279	0.0011	CcSEcCtD
Gefitinib—Infection—Lisinopril—systemic scleroderma	0.000278	0.0011	CcSEcCtD
Gefitinib—Anaemia—Mycophenolate mofetil—systemic scleroderma	0.000278	0.0011	CcSEcCtD
Gefitinib—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.000277	0.0011	CcSEcCtD
Gefitinib—Shock—Lisinopril—systemic scleroderma	0.000276	0.00109	CcSEcCtD
Gefitinib—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.000275	0.00109	CcSEcCtD
Gefitinib—Thrombocytopenia—Lisinopril—systemic scleroderma	0.000274	0.00108	CcSEcCtD
Gefitinib—Abdominal pain—Azathioprine—systemic scleroderma	0.000273	0.00108	CcSEcCtD
Gefitinib—Body temperature increased—Azathioprine—systemic scleroderma	0.000273	0.00108	CcSEcCtD
Gefitinib—Skin disorder—Lisinopril—systemic scleroderma	0.000272	0.00108	CcSEcCtD
Gefitinib—Malaise—Mycophenolate mofetil—systemic scleroderma	0.000271	0.00107	CcSEcCtD
Gefitinib—Diarrhoea—Captopril—systemic scleroderma	0.000271	0.00107	CcSEcCtD
Gefitinib—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.00027	0.00107	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000269	0.00106	CcSEcCtD
Gefitinib—Fatigue—Mycophenolic acid—systemic scleroderma	0.000268	0.00106	CcSEcCtD
Gefitinib—Nausea—Mometasone—systemic scleroderma	0.000268	0.00106	CcSEcCtD
Gefitinib—Anorexia—Lisinopril—systemic scleroderma	0.000267	0.00106	CcSEcCtD
Gefitinib—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000267	0.00105	CcSEcCtD
Gefitinib—Pain—Mycophenolic acid—systemic scleroderma	0.000266	0.00105	CcSEcCtD
Gefitinib—Constipation—Mycophenolic acid—systemic scleroderma	0.000266	0.00105	CcSEcCtD
Gefitinib—Weight decreased—Prednisone—systemic scleroderma	0.000265	0.00105	CcSEcCtD
Gefitinib—Cough—Mycophenolate mofetil—systemic scleroderma	0.000262	0.00104	CcSEcCtD
Gefitinib—Hypotension—Lisinopril—systemic scleroderma	0.000262	0.00104	CcSEcCtD
Gefitinib—Urticaria—Leflunomide—systemic scleroderma	0.000259	0.00102	CcSEcCtD
Gefitinib—ABCB1—digestive system—systemic scleroderma	0.000259	0.00397	CbGeAlD
Gefitinib—Abdominal pain—Leflunomide—systemic scleroderma	0.000258	0.00102	CcSEcCtD
Gefitinib—Body temperature increased—Leflunomide—systemic scleroderma	0.000258	0.00102	CcSEcCtD
Gefitinib—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	0.000255	0.00101	CcSEcCtD
Gefitinib—Hypersensitivity—Azathioprine—systemic scleroderma	0.000254	0.00101	CcSEcCtD
Gefitinib—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000254	0.00101	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000254	0.00101	CcSEcCtD
Gefitinib—Vomiting—Captopril—systemic scleroderma	0.000252	0.000995	CcSEcCtD
Gefitinib—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.00025	0.00099	CcSEcCtD
Gefitinib—Dyspnoea—Lisinopril—systemic scleroderma	0.00025	0.000988	CcSEcCtD
Gefitinib—Rash—Captopril—systemic scleroderma	0.000249	0.000987	CcSEcCtD
Gefitinib—Dermatitis—Captopril—systemic scleroderma	0.000249	0.000986	CcSEcCtD
Gefitinib—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000246	0.000972	CcSEcCtD
Gefitinib—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000246	0.000972	CcSEcCtD
Gefitinib—Infection—Mycophenolate mofetil—systemic scleroderma	0.000244	0.000965	CcSEcCtD
Gefitinib—Decreased appetite—Lisinopril—systemic scleroderma	0.000244	0.000963	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000242	0.000957	CcSEcCtD
Gefitinib—Fatigue—Lisinopril—systemic scleroderma	0.000242	0.000955	CcSEcCtD
Gefitinib—Shock—Mycophenolate mofetil—systemic scleroderma	0.000242	0.000955	CcSEcCtD
Gefitinib—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000241	0.000952	CcSEcCtD
Gefitinib—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.00024	0.000951	CcSEcCtD
Gefitinib—Hypersensitivity—Leflunomide—systemic scleroderma	0.00024	0.00095	CcSEcCtD
Gefitinib—Pancreatitis—Methotrexate—systemic scleroderma	0.00024	0.000948	CcSEcCtD
Gefitinib—Pain—Lisinopril—systemic scleroderma	0.00024	0.000948	CcSEcCtD
Gefitinib—Constipation—Lisinopril—systemic scleroderma	0.00024	0.000948	CcSEcCtD
Gefitinib—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000238	0.000943	CcSEcCtD
Gefitinib—Diarrhoea—Azathioprine—systemic scleroderma	0.000236	0.000934	CcSEcCtD
Gefitinib—Haemoglobin—Prednisone—systemic scleroderma	0.000235	0.000931	CcSEcCtD
Gefitinib—Nausea—Captopril—systemic scleroderma	0.000235	0.000929	CcSEcCtD
Gefitinib—Haemorrhage—Prednisone—systemic scleroderma	0.000234	0.000926	CcSEcCtD
Gefitinib—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000234	0.000925	CcSEcCtD
Gefitinib—Asthenia—Leflunomide—systemic scleroderma	0.000234	0.000925	CcSEcCtD
Gefitinib—Pruritus—Leflunomide—systemic scleroderma	0.000231	0.000912	CcSEcCtD
Gefitinib—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000229	0.000907	CcSEcCtD
Gefitinib—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000229	0.000906	CcSEcCtD
Gefitinib—Asthenia—Mycophenolic acid—systemic scleroderma	0.000223	0.000883	CcSEcCtD
Gefitinib—Diarrhoea—Leflunomide—systemic scleroderma	0.000223	0.000882	CcSEcCtD
Gefitinib—Urticaria—Lisinopril—systemic scleroderma	0.000223	0.00088	CcSEcCtD
Gefitinib—Abdominal pain—Lisinopril—systemic scleroderma	0.000221	0.000876	CcSEcCtD
Gefitinib—Body temperature increased—Lisinopril—systemic scleroderma	0.000221	0.000876	CcSEcCtD
Gefitinib—Pruritus—Mycophenolic acid—systemic scleroderma	0.00022	0.00087	CcSEcCtD
Gefitinib—Vomiting—Azathioprine—systemic scleroderma	0.00022	0.000868	CcSEcCtD
Gefitinib—Pneumonia—Methotrexate—systemic scleroderma	0.000219	0.000867	CcSEcCtD
Gefitinib—Eye disorder—Prednisone—systemic scleroderma	0.000219	0.000866	CcSEcCtD
Gefitinib—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000219	0.000866	CcSEcCtD
Gefitinib—Infestation NOS—Methotrexate—systemic scleroderma	0.000218	0.000862	CcSEcCtD
Gefitinib—Infestation—Methotrexate—systemic scleroderma	0.000218	0.000862	CcSEcCtD
Gefitinib—Rash—Azathioprine—systemic scleroderma	0.000218	0.000861	CcSEcCtD
Gefitinib—Dermatitis—Azathioprine—systemic scleroderma	0.000218	0.00086	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.000216	0.000855	CcSEcCtD
Gefitinib—ABCB1—lung—systemic scleroderma	0.000216	0.00332	CbGeAlD
Gefitinib—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000213	0.000844	CcSEcCtD
Gefitinib—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000213	0.000842	CcSEcCtD
Gefitinib—Stomatitis—Methotrexate—systemic scleroderma	0.000213	0.000841	CcSEcCtD
Gefitinib—Angiopathy—Prednisone—systemic scleroderma	0.000213	0.00084	CcSEcCtD
Gefitinib—Conjunctivitis—Methotrexate—systemic scleroderma	0.000212	0.000838	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000212	0.000838	CcSEcCtD
Gefitinib—Constipation—Mycophenolate mofetil—systemic scleroderma	0.00021	0.00083	CcSEcCtD
Gefitinib—Pain—Mycophenolate mofetil—systemic scleroderma	0.00021	0.00083	CcSEcCtD
Gefitinib—Arrhythmia—Prednisone—systemic scleroderma	0.000209	0.000827	CcSEcCtD
Gefitinib—Haematuria—Methotrexate—systemic scleroderma	0.000208	0.000822	CcSEcCtD
Gefitinib—Vomiting—Leflunomide—systemic scleroderma	0.000207	0.00082	CcSEcCtD
Gefitinib—Alopecia—Prednisone—systemic scleroderma	0.000207	0.000819	CcSEcCtD
Gefitinib—Hypersensitivity—Lisinopril—systemic scleroderma	0.000206	0.000816	CcSEcCtD
Gefitinib—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.000206	0.000816	CcSEcCtD
Gefitinib—Epistaxis—Methotrexate—systemic scleroderma	0.000206	0.000813	CcSEcCtD
Gefitinib—Rash—Leflunomide—systemic scleroderma	0.000206	0.000813	CcSEcCtD
Gefitinib—Dermatitis—Leflunomide—systemic scleroderma	0.000205	0.000812	CcSEcCtD
Gefitinib—Nausea—Azathioprine—systemic scleroderma	0.000205	0.000811	CcSEcCtD
Gefitinib—Malnutrition—Prednisone—systemic scleroderma	0.000204	0.000806	CcSEcCtD
Gefitinib—Asthenia—Lisinopril—systemic scleroderma	0.000201	0.000795	CcSEcCtD
Gefitinib—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000201	0.000794	CcSEcCtD
Gefitinib—Pruritus—Lisinopril—systemic scleroderma	0.000198	0.000784	CcSEcCtD
Gefitinib—Vomiting—Mycophenolic acid—systemic scleroderma	0.000198	0.000782	CcSEcCtD
Gefitinib—Haemoglobin—Methotrexate—systemic scleroderma	0.000197	0.000778	CcSEcCtD
Gefitinib—Rash—Mycophenolic acid—systemic scleroderma	0.000196	0.000776	CcSEcCtD
Gefitinib—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000196	0.000775	CcSEcCtD
Gefitinib—Haemorrhage—Methotrexate—systemic scleroderma	0.000196	0.000774	CcSEcCtD
Gefitinib—Hepatitis—Methotrexate—systemic scleroderma	0.000196	0.000774	CcSEcCtD
Gefitinib—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000195	0.000771	CcSEcCtD
Gefitinib—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000194	0.000767	CcSEcCtD
Gefitinib—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000194	0.000767	CcSEcCtD
Gefitinib—Nausea—Leflunomide—systemic scleroderma	0.000194	0.000766	CcSEcCtD
Gefitinib—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000193	0.000764	CcSEcCtD
Gefitinib—Urethral disorder—Methotrexate—systemic scleroderma	0.000192	0.000759	CcSEcCtD
Gefitinib—Diarrhoea—Lisinopril—systemic scleroderma	0.000192	0.000758	CcSEcCtD
Gefitinib—Anaemia—Prednisone—systemic scleroderma	0.000188	0.000745	CcSEcCtD
Gefitinib—Angioedema—Prednisone—systemic scleroderma	0.000186	0.000737	CcSEcCtD
Gefitinib—Erythema multiforme—Methotrexate—systemic scleroderma	0.000185	0.000732	CcSEcCtD
Gefitinib—Nausea—Mycophenolic acid—systemic scleroderma	0.000185	0.000731	CcSEcCtD
Gefitinib—Malaise—Prednisone—systemic scleroderma	0.000184	0.000727	CcSEcCtD
Gefitinib—Eye disorder—Methotrexate—systemic scleroderma	0.000183	0.000723	CcSEcCtD
Gefitinib—Cardiac disorder—Methotrexate—systemic scleroderma	0.000182	0.000718	CcSEcCtD
Gefitinib—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000181	0.000715	CcSEcCtD
Gefitinib—Vomiting—Lisinopril—systemic scleroderma	0.000178	0.000705	CcSEcCtD
Gefitinib—Angiopathy—Methotrexate—systemic scleroderma	0.000178	0.000702	CcSEcCtD
Gefitinib—Rash—Lisinopril—systemic scleroderma	0.000177	0.000699	CcSEcCtD
Gefitinib—Dermatitis—Lisinopril—systemic scleroderma	0.000177	0.000698	CcSEcCtD
Gefitinib—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000176	0.000698	CcSEcCtD
Gefitinib—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000176	0.000697	CcSEcCtD
Gefitinib—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000174	0.000687	CcSEcCtD
Gefitinib—Alopecia—Methotrexate—systemic scleroderma	0.000173	0.000684	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000172	0.000682	CcSEcCtD
Gefitinib—Malnutrition—Methotrexate—systemic scleroderma	0.00017	0.000674	CcSEcCtD
Gefitinib—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000168	0.000664	CcSEcCtD
Gefitinib—Nausea—Lisinopril—systemic scleroderma	0.000166	0.000658	CcSEcCtD
Gefitinib—Infection—Prednisone—systemic scleroderma	0.000165	0.000654	CcSEcCtD
Gefitinib—Shock—Prednisone—systemic scleroderma	0.000164	0.000647	CcSEcCtD
Gefitinib—Nervous system disorder—Prednisone—systemic scleroderma	0.000163	0.000645	CcSEcCtD
Gefitinib—Skin disorder—Prednisone—systemic scleroderma	0.000162	0.000639	CcSEcCtD
Gefitinib—Anorexia—Prednisone—systemic scleroderma	0.000159	0.000627	CcSEcCtD
Gefitinib—Anaemia—Methotrexate—systemic scleroderma	0.000158	0.000623	CcSEcCtD
Gefitinib—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000156	0.000617	CcSEcCtD
Gefitinib—Rash—Mycophenolate mofetil—systemic scleroderma	0.000155	0.000612	CcSEcCtD
Gefitinib—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000155	0.000612	CcSEcCtD
Gefitinib—Malaise—Methotrexate—systemic scleroderma	0.000154	0.000608	CcSEcCtD
Gefitinib—Cough—Methotrexate—systemic scleroderma	0.000149	0.000588	CcSEcCtD
Gefitinib—ERBB3—Innate Immune System—CD247—systemic scleroderma	0.000147	0.00141	CbGpPWpGaD
Gefitinib—MKNK1—Disease—HSPG2—systemic scleroderma	0.000147	0.00141	CbGpPWpGaD
Gefitinib—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000146	0.000577	CcSEcCtD
Gefitinib—IRAK1—Signaling by Interleukins—IL1B—systemic scleroderma	0.000145	0.00139	CbGpPWpGaD
Gefitinib—Decreased appetite—Prednisone—systemic scleroderma	0.000145	0.000572	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000144	0.00057	CcSEcCtD
Gefitinib—CSNK1E—Disease—TGFBI—systemic scleroderma	0.000144	0.00137	CbGpPWpGaD
Gefitinib—Fatigue—Prednisone—systemic scleroderma	0.000143	0.000567	CcSEcCtD
Gefitinib—Constipation—Prednisone—systemic scleroderma	0.000142	0.000563	CcSEcCtD
Gefitinib—MKNK1—Disease—CSK—systemic scleroderma	0.000142	0.00136	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—CD247—systemic scleroderma	0.000141	0.00135	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—SMAD7—systemic scleroderma	0.000141	0.00135	CbGpPWpGaD
Gefitinib—EPHA6—Axon guidance—MMP2—systemic scleroderma	0.000141	0.00135	CbGpPWpGaD
Gefitinib—ABCB1—HIF-1-alpha transcription factor network—EDN1—systemic scleroderma	0.00014	0.00134	CbGpPWpGaD
Gefitinib—EGFR—LPA receptor mediated events—MMP9—systemic scleroderma	0.000139	0.00133	CbGpPWpGaD
Gefitinib—Infection—Methotrexate—systemic scleroderma	0.000138	0.000546	CcSEcCtD
Gefitinib—ERBB3—Innate Immune System—TNFAIP3—systemic scleroderma	0.000138	0.00132	CbGpPWpGaD
Gefitinib—IRAK1—Cytokine Signaling in Immune system—HLA-DQB1—systemic scleroderma	0.000137	0.00131	CbGpPWpGaD
Gefitinib—Nervous system disorder—Methotrexate—systemic scleroderma	0.000136	0.000539	CcSEcCtD
Gefitinib—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000136	0.000538	CcSEcCtD
Gefitinib—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000136	0.000538	CcSEcCtD
Gefitinib—EGFR—AGE/RAGE pathway—MMP9—systemic scleroderma	0.000135	0.0013	CbGpPWpGaD
Gefitinib—Skin disorder—Methotrexate—systemic scleroderma	0.000135	0.000534	CcSEcCtD
Gefitinib—ALB—Vitamin B12 Metabolism—CCL2—systemic scleroderma	0.000134	0.00128	CbGpPWpGaD
Gefitinib—MKNK1—Disease—CD247—systemic scleroderma	0.000134	0.00128	CbGpPWpGaD
Gefitinib—Anorexia—Methotrexate—systemic scleroderma	0.000133	0.000524	CcSEcCtD
Gefitinib—ERBB3—Signaling by SCF-KIT—MMP9—systemic scleroderma	0.000133	0.00127	CbGpPWpGaD
Gefitinib—Urticaria—Prednisone—systemic scleroderma	0.000132	0.000523	CcSEcCtD
Gefitinib—Abdominal pain—Prednisone—systemic scleroderma	0.000132	0.00052	CcSEcCtD
Gefitinib—Body temperature increased—Prednisone—systemic scleroderma	0.000132	0.00052	CcSEcCtD
Gefitinib—CHEK2—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	0.000131	0.00126	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—BLK—systemic scleroderma	0.000131	0.00125	CbGpPWpGaD
Gefitinib—EGFR—MAPK Signaling Pathway—IL1A—systemic scleroderma	0.00013	0.00125	CbGpPWpGaD
Gefitinib—Hypotension—Methotrexate—systemic scleroderma	0.00013	0.000514	CcSEcCtD
Gefitinib—IRAK1—Cytokine Signaling in Immune system—IL1A—systemic scleroderma	0.00013	0.00124	CbGpPWpGaD
Gefitinib—ALB—Platelet activation, signaling and aggregation—SELP—systemic scleroderma	0.000127	0.00122	CbGpPWpGaD
Gefitinib—MAP2K5—MAPK Signaling Pathway—IL1B—systemic scleroderma	0.000127	0.00121	CbGpPWpGaD
Gefitinib—ABCB1—Allograft Rejection—HLA-DQB1—systemic scleroderma	0.000127	0.00121	CbGpPWpGaD
Gefitinib—Dyspnoea—Methotrexate—systemic scleroderma	0.000124	0.00049	CcSEcCtD
Gefitinib—IRAK1—Innate Immune System—CD247—systemic scleroderma	0.000123	0.00117	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—ITGAM—systemic scleroderma	0.000123	0.00117	CbGpPWpGaD
Gefitinib—Hypersensitivity—Prednisone—systemic scleroderma	0.000123	0.000485	CcSEcCtD
Gefitinib—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL1B—systemic scleroderma	0.000121	0.00116	CbGpPWpGaD
Gefitinib—Decreased appetite—Methotrexate—systemic scleroderma	0.000121	0.000478	CcSEcCtD
Gefitinib—ABCB1—Allograft Rejection—IL1A—systemic scleroderma	0.00012	0.00115	CbGpPWpGaD
Gefitinib—EGFR—Integrated Breast Cancer Pathway—MMP1—systemic scleroderma	0.00012	0.00115	CbGpPWpGaD
Gefitinib—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.00012	0.000475	CcSEcCtD
Gefitinib—Fatigue—Methotrexate—systemic scleroderma	0.00012	0.000474	CcSEcCtD
Gefitinib—ABCB1—Allograft Rejection—CD40LG—systemic scleroderma	0.00012	0.00115	CbGpPWpGaD
Gefitinib—ERBB3—Disease—SMAD7—systemic scleroderma	0.00012	0.00114	CbGpPWpGaD
Gefitinib—Asthenia—Prednisone—systemic scleroderma	0.000119	0.000472	CcSEcCtD
Gefitinib—EGFR—Spinal Cord Injury—CCL2—systemic scleroderma	0.000119	0.00114	CbGpPWpGaD
Gefitinib—Pain—Methotrexate—systemic scleroderma	0.000119	0.00047	CcSEcCtD
Gefitinib—ALB—Platelet activation, signaling and aggregation—RHOB—systemic scleroderma	0.000119	0.00114	CbGpPWpGaD
Gefitinib—IRAK1—Regulation of toll-like receptor signaling pathway—IL1B—systemic scleroderma	0.000118	0.00113	CbGpPWpGaD
Gefitinib—Pruritus—Prednisone—systemic scleroderma	0.000118	0.000466	CcSEcCtD
Gefitinib—IRAK1—Innate Immune System—TNFAIP3—systemic scleroderma	0.000115	0.0011	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—HSPG2—systemic scleroderma	0.000115	0.0011	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—CSK—systemic scleroderma	0.000114	0.0011	CbGpPWpGaD
Gefitinib—Diarrhoea—Prednisone—systemic scleroderma	0.000114	0.00045	CcSEcCtD
Gefitinib—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000114	0.00045	CcSEcCtD
Gefitinib—IRAK4—Immune System—IRF5—systemic scleroderma	0.000113	0.00108	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—CSK—systemic scleroderma	0.000111	0.00106	CbGpPWpGaD
Gefitinib—Urticaria—Methotrexate—systemic scleroderma	0.00011	0.000437	CcSEcCtD
Gefitinib—Abdominal pain—Methotrexate—systemic scleroderma	0.00011	0.000435	CcSEcCtD
Gefitinib—Body temperature increased—Methotrexate—systemic scleroderma	0.00011	0.000435	CcSEcCtD
Gefitinib—CSNK1E—Signaling Pathways—SMAD7—systemic scleroderma	0.00011	0.00105	CbGpPWpGaD
Gefitinib—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CTGF—systemic scleroderma	0.00011	0.00105	CbGpPWpGaD
Gefitinib—ERBB3—Disease—TGFBI—systemic scleroderma	0.000109	0.00105	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—RHOB—systemic scleroderma	0.000109	0.00105	CbGpPWpGaD
Gefitinib—ALB—Folate Metabolism—CCL2—systemic scleroderma	0.000109	0.00104	CbGpPWpGaD
Gefitinib—EGFR—Regulation of Telomerase—TGFB1—systemic scleroderma	0.000109	0.00104	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—RHOB—systemic scleroderma	0.000108	0.00104	CbGpPWpGaD
Gefitinib—ALB—Platelet activation, signaling and aggregation—CSK—systemic scleroderma	0.000108	0.00104	CbGpPWpGaD
Gefitinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—systemic scleroderma	0.000108	0.00103	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—IRF8—systemic scleroderma	0.000108	0.00103	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—ITGAM—systemic scleroderma	0.000108	0.00103	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—CD247—systemic scleroderma	0.000108	0.00103	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—CTLA4—systemic scleroderma	0.000107	0.00103	CbGpPWpGaD
Gefitinib—EPHA6—Axon guidance—MMP9—systemic scleroderma	0.000106	0.00101	CbGpPWpGaD
Gefitinib—Vomiting—Prednisone—systemic scleroderma	0.000106	0.000418	CcSEcCtD
Gefitinib—Rash—Prednisone—systemic scleroderma	0.000105	0.000415	CcSEcCtD
Gefitinib—Dermatitis—Prednisone—systemic scleroderma	0.000105	0.000415	CcSEcCtD
Gefitinib—CSNK1E—Disease—CD247—systemic scleroderma	0.000104	0.000995	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—HSPG2—systemic scleroderma	0.000103	0.000986	CbGpPWpGaD
Gefitinib—Hypersensitivity—Methotrexate—systemic scleroderma	0.000102	0.000405	CcSEcCtD
Gefitinib—IRAK4—Cytokine Signaling in Immune system—IL1B—systemic scleroderma	0.000102	0.000975	CbGpPWpGaD
Gefitinib—ALB—Vitamin B12 Metabolism—IL1B—systemic scleroderma	0.000102	0.000973	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—TNFAIP3—systemic scleroderma	0.000101	0.000964	CbGpPWpGaD
Gefitinib—EPHA6—Developmental Biology—MMP2—systemic scleroderma	0.000101	0.000963	CbGpPWpGaD
Gefitinib—Asthenia—Methotrexate—systemic scleroderma	9.98e-05	0.000395	CcSEcCtD
Gefitinib—IRAK4—Immune System—BLK—systemic scleroderma	9.96e-05	0.000953	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—CSK—systemic scleroderma	9.96e-05	0.000953	CbGpPWpGaD
Gefitinib—Nausea—Prednisone—systemic scleroderma	9.88e-05	0.000391	CcSEcCtD
Gefitinib—EGFR—Direct p53 effectors—MMP2—systemic scleroderma	9.88e-05	0.000945	CbGpPWpGaD
Gefitinib—MAP2K5—MAPK Signaling Pathway—TGFB1—systemic scleroderma	9.85e-05	0.000943	CbGpPWpGaD
Gefitinib—Pruritus—Methotrexate—systemic scleroderma	9.84e-05	0.000389	CcSEcCtD
Gefitinib—Diarrhoea—Methotrexate—systemic scleroderma	9.52e-05	0.000376	CcSEcCtD
Gefitinib—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic scleroderma	9.42e-05	0.000901	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—CSK—systemic scleroderma	9.13e-05	0.000873	CbGpPWpGaD
Gefitinib—EGFR—Spinal Cord Injury—IL1B—systemic scleroderma	9.03e-05	0.000864	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—IRF5—systemic scleroderma	8.98e-05	0.000859	CbGpPWpGaD
Gefitinib—Vomiting—Methotrexate—systemic scleroderma	8.84e-05	0.00035	CcSEcCtD
Gefitinib—ERBB3—Adaptive Immune System—HLA-DQB1—systemic scleroderma	8.83e-05	0.000845	CbGpPWpGaD
Gefitinib—Rash—Methotrexate—systemic scleroderma	8.77e-05	0.000347	CcSEcCtD
Gefitinib—Dermatitis—Methotrexate—systemic scleroderma	8.76e-05	0.000346	CcSEcCtD
Gefitinib—ERBB3—Disease—HSPG2—systemic scleroderma	8.72e-05	0.000835	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—SMAD7—systemic scleroderma	8.69e-05	0.000831	CbGpPWpGaD
Gefitinib—ALB—Selenium Micronutrient Network—CCL2—systemic scleroderma	8.67e-05	0.000829	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—IRF8—systemic scleroderma	8.58e-05	0.000821	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—ITGAM—systemic scleroderma	8.58e-05	0.000821	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—CD247—systemic scleroderma	8.58e-05	0.000821	CbGpPWpGaD
Gefitinib—EGFR—Spinal Cord Injury—MMP9—systemic scleroderma	8.51e-05	0.000814	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—RHOB—systemic scleroderma	8.5e-05	0.000813	CbGpPWpGaD
Gefitinib—ERBB3—Disease—CSK—systemic scleroderma	8.43e-05	0.000806	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—CSK—systemic scleroderma	8.38e-05	0.000801	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—SMAD7—systemic scleroderma	8.37e-05	0.000801	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—CD40LG—systemic scleroderma	8.34e-05	0.000798	CbGpPWpGaD
Gefitinib—ALB—Folate Metabolism—IL1B—systemic scleroderma	8.28e-05	0.000792	CbGpPWpGaD
Gefitinib—Nausea—Methotrexate—systemic scleroderma	8.26e-05	0.000327	CcSEcCtD
Gefitinib—EGFR—EGF/EGFR Signaling Pathway—NOS3—systemic scleroderma	8.23e-05	0.000788	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—CD247—systemic scleroderma	8.2e-05	0.000785	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—ITGAM—systemic scleroderma	8.2e-05	0.000785	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—CTLA4—systemic scleroderma	8.16e-05	0.00078	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—TNFAIP3—systemic scleroderma	8.03e-05	0.000769	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—HSPG2—systemic scleroderma	8.02e-05	0.000767	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—BLK—systemic scleroderma	7.94e-05	0.00076	CbGpPWpGaD
Gefitinib—ERBB3—Disease—CD247—systemic scleroderma	7.92e-05	0.000758	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—CD247—systemic scleroderma	7.88e-05	0.000753	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—CSK—systemic scleroderma	7.74e-05	0.000741	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—TNFAIP3—systemic scleroderma	7.68e-05	0.000735	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—CSK—systemic scleroderma	7.6e-05	0.000727	CbGpPWpGaD
Gefitinib—EPHA6—Developmental Biology—MMP9—systemic scleroderma	7.57e-05	0.000724	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—IRF5—systemic scleroderma	7.48e-05	0.000715	CbGpPWpGaD
Gefitinib—EGFR—Signaling by SCF-KIT—MMP9—systemic scleroderma	7.38e-05	0.000706	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—BLK—systemic scleroderma	7.29e-05	0.000697	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—IRF8—systemic scleroderma	7.14e-05	0.000683	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—ITGAM—systemic scleroderma	7.14e-05	0.000683	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—CD247—systemic scleroderma	7.14e-05	0.000683	CbGpPWpGaD
Gefitinib—EGFR—Spinal Cord Injury—TGFB1—systemic scleroderma	7.01e-05	0.000671	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—SMAD7—systemic scleroderma	6.97e-05	0.000667	CbGpPWpGaD
Gefitinib—EGFR—MAPK Signaling Pathway—IL1B—systemic scleroderma	6.8e-05	0.000651	CbGpPWpGaD
Gefitinib—IRAK1—Cytokine Signaling in Immune system—IL1B—systemic scleroderma	6.76e-05	0.000647	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—RHOB—systemic scleroderma	6.72e-05	0.000643	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—HLA-DQB1—systemic scleroderma	6.72e-05	0.000643	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—TNFAIP3—systemic scleroderma	6.69e-05	0.00064	CbGpPWpGaD
Gefitinib—EGFR—Disease—SMAD7—systemic scleroderma	6.66e-05	0.000637	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—BLK—systemic scleroderma	6.61e-05	0.000632	CbGpPWpGaD
Gefitinib—ALB—Selenium Micronutrient Network—IL1B—systemic scleroderma	6.57e-05	0.000629	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—SELP—systemic scleroderma	6.56e-05	0.000628	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—CTLA4—systemic scleroderma	6.5e-05	0.000622	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—RHOB—systemic scleroderma	6.48e-05	0.00062	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—IL1A—systemic scleroderma	6.38e-05	0.00061	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—CD40LG—systemic scleroderma	6.34e-05	0.000607	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—HSPG2—systemic scleroderma	6.34e-05	0.000606	CbGpPWpGaD
Gefitinib—ABCB1—Allograft Rejection—IL1B—systemic scleroderma	6.28e-05	0.000601	CbGpPWpGaD
Gefitinib—EPHA6—Developmental Biology—TGFB1—systemic scleroderma	6.24e-05	0.000597	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—RHOB—systemic scleroderma	6.13e-05	0.000586	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—CSK—systemic scleroderma	6.12e-05	0.000586	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—HSPG2—systemic scleroderma	6.11e-05	0.000585	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—RHOB—systemic scleroderma	6.11e-05	0.000584	CbGpPWpGaD
Gefitinib—EGFR—Disease—TGFBI—systemic scleroderma	6.09e-05	0.000583	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—CTLA4—systemic scleroderma	5.97e-05	0.000571	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—CSK—systemic scleroderma	5.9e-05	0.000565	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	5.77e-05	0.000552	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—EDN1—systemic scleroderma	5.58e-05	0.000534	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—CSK—systemic scleroderma	5.58e-05	0.000534	CbGpPWpGaD
Gefitinib—ALB—Platelet degranulation—TGFB1—systemic scleroderma	5.51e-05	0.000528	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—CTLA4—systemic scleroderma	5.41e-05	0.000518	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—RHOB—systemic scleroderma	5.39e-05	0.000516	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—HLA-DQB1—systemic scleroderma	5.36e-05	0.000512	CbGpPWpGaD
Gefitinib—EGFR—MAPK Signaling Pathway—TGFB1—systemic scleroderma	5.29e-05	0.000506	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	5.26e-05	0.000503	CbGpPWpGaD
Gefitinib—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—systemic scleroderma	5.25e-05	0.000503	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—ITGAM—systemic scleroderma	5.25e-05	0.000502	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—HSPG2—systemic scleroderma	5.09e-05	0.000487	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—IL1A—systemic scleroderma	5.09e-05	0.000487	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CSK—systemic scleroderma	5.08e-05	0.000486	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—CD40LG—systemic scleroderma	5.06e-05	0.000484	CbGpPWpGaD
Gefitinib—EGFR—Axon guidance—MMP2—systemic scleroderma	5.05e-05	0.000483	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IRF5—systemic scleroderma	5e-05	0.000478	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—HLA-DQB1—systemic scleroderma	4.92e-05	0.00047	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CSK—systemic scleroderma	4.91e-05	0.00047	CbGpPWpGaD
Gefitinib—ABCB1—Allograft Rejection—TGFB1—systemic scleroderma	4.88e-05	0.000467	CbGpPWpGaD
Gefitinib—EGFR—Disease—HSPG2—systemic scleroderma	4.86e-05	0.000465	CbGpPWpGaD
Gefitinib—MKNK1—Disease—NOS3—systemic scleroderma	4.86e-05	0.000465	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IRF8—systemic scleroderma	4.78e-05	0.000457	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CD247—systemic scleroderma	4.78e-05	0.000457	CbGpPWpGaD
Gefitinib—EGFR—Immune System—ITGAM—systemic scleroderma	4.78e-05	0.000457	CbGpPWpGaD
Gefitinib—EGFR—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	4.77e-05	0.000456	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	4.72e-05	0.000452	CbGpPWpGaD
Gefitinib—EGFR—Disease—CSK—systemic scleroderma	4.69e-05	0.000449	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—SMAD7—systemic scleroderma	4.66e-05	0.000446	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—CD40LG—systemic scleroderma	4.64e-05	0.000444	CbGpPWpGaD
Gefitinib—EGFR—Immune System—TNFAIP3—systemic scleroderma	4.47e-05	0.000428	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—HLA-DQB1—systemic scleroderma	4.46e-05	0.000427	CbGpPWpGaD
Gefitinib—EGFR—Immune System—BLK—systemic scleroderma	4.42e-05	0.000423	CbGpPWpGaD
Gefitinib—EGFR—Disease—CD247—systemic scleroderma	4.41e-05	0.000422	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	4.37e-05	0.000419	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—EDN1—systemic scleroderma	4.34e-05	0.000415	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	4.31e-05	0.000412	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—IL1A—systemic scleroderma	4.23e-05	0.000405	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—CD40LG—systemic scleroderma	4.21e-05	0.000403	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	3.99e-05	0.000381	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—CCL2—systemic scleroderma	3.82e-05	0.000365	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—HSPG2—systemic scleroderma	3.8e-05	0.000363	CbGpPWpGaD
Gefitinib—EGFR—Axon guidance—MMP9—systemic scleroderma	3.79e-05	0.000363	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—NOS3—systemic scleroderma	3.78e-05	0.000361	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CTLA4—systemic scleroderma	3.62e-05	0.000346	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—RHOB—systemic scleroderma	3.61e-05	0.000345	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—MMP2—systemic scleroderma	3.6e-05	0.000345	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	3.58e-05	0.000342	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—EDN1—systemic scleroderma	3.43e-05	0.000328	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—HSPG2—systemic scleroderma	3.4e-05	0.000325	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—NOS3—systemic scleroderma	3.4e-05	0.000325	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—IL1B—systemic scleroderma	3.33e-05	0.000318	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—EDN1—systemic scleroderma	3.31e-05	0.000316	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CSK—systemic scleroderma	3.28e-05	0.000314	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	3.26e-05	0.000312	CbGpPWpGaD
Gefitinib—MKNK1—Disease—TGFB1—systemic scleroderma	3.21e-05	0.000307	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—EDN1—systemic scleroderma	3.12e-05	0.000298	CbGpPWpGaD
Gefitinib—EGFR—Immune System—HLA-DQB1—systemic scleroderma	2.98e-05	0.000285	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—CCL2—systemic scleroderma	2.97e-05	0.000284	CbGpPWpGaD
Gefitinib—ERBB3—Disease—NOS3—systemic scleroderma	2.88e-05	0.000275	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—CTGF—systemic scleroderma	2.88e-05	0.000275	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IL1A—systemic scleroderma	2.83e-05	0.000271	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CD40LG—systemic scleroderma	2.82e-05	0.000269	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—EDN1—systemic scleroderma	2.75e-05	0.000263	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—MMP9—systemic scleroderma	2.73e-05	0.000261	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—HSPG2—systemic scleroderma	2.72e-05	0.00026	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—MMP9—systemic scleroderma	2.71e-05	0.000259	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—IL1B—systemic scleroderma	2.65e-05	0.000254	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—NOS3—systemic scleroderma	2.65e-05	0.000253	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—MMP1—systemic scleroderma	2.63e-05	0.000252	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—HSPG2—systemic scleroderma	2.57e-05	0.000246	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—TGFB1—systemic scleroderma	2.5e-05	0.000239	CbGpPWpGaD
Gefitinib—ALB—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	2.45e-05	0.000234	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	2.41e-05	0.00023	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—CCL2—systemic scleroderma	2.35e-05	0.000224	CbGpPWpGaD
Gefitinib—ALB—Metabolism—HSPG2—systemic scleroderma	2.34e-05	0.000224	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—CCL2—systemic scleroderma	2.26e-05	0.000216	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—TGFB1—systemic scleroderma	2.25e-05	0.000215	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—TGFB1—systemic scleroderma	2.23e-05	0.000213	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—IL1B—systemic scleroderma	2.21e-05	0.000211	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—CCL2—systemic scleroderma	2.13e-05	0.000204	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—MMP9—systemic scleroderma	2.12e-05	0.000203	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—HSPG2—systemic scleroderma	2.1e-05	0.000201	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—NOS3—systemic scleroderma	2.09e-05	0.0002	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—CTGF—systemic scleroderma	2.06e-05	0.000197	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—HSPG2—systemic scleroderma	2.05e-05	0.000196	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—NOS3—systemic scleroderma	2.02e-05	0.000193	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—CTGF—systemic scleroderma	1.95e-05	0.000186	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—HSPG2—systemic scleroderma	1.93e-05	0.000185	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—HSPG2—systemic scleroderma	1.92e-05	0.000184	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—NOS3—systemic scleroderma	1.91e-05	0.000182	CbGpPWpGaD
Gefitinib—ERBB3—Disease—TGFB1—systemic scleroderma	1.9e-05	0.000182	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CCL2—systemic scleroderma	1.88e-05	0.00018	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—EDN1—systemic scleroderma	1.84e-05	0.000176	CbGpPWpGaD
Gefitinib—ALB—Metabolism—CTGF—systemic scleroderma	1.78e-05	0.00017	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—TGFB1—systemic scleroderma	1.75e-05	0.000167	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—NOS3—systemic scleroderma	1.68e-05	0.000161	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—MMP9—systemic scleroderma	1.68e-05	0.00016	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—MMP9—systemic scleroderma	1.62e-05	0.000155	CbGpPWpGaD
Gefitinib—EGFR—Disease—NOS3—systemic scleroderma	1.6e-05	0.000153	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CTGF—systemic scleroderma	1.59e-05	0.000153	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CTGF—systemic scleroderma	1.56e-05	0.000149	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IL1B—systemic scleroderma	1.48e-05	0.000141	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CTGF—systemic scleroderma	1.47e-05	0.00014	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CTGF—systemic scleroderma	1.45e-05	0.000139	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—TGFB1—systemic scleroderma	1.38e-05	0.000132	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MMP9—systemic scleroderma	1.35e-05	0.000129	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—TGFB1—systemic scleroderma	1.33e-05	0.000128	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—HSPG2—systemic scleroderma	1.26e-05	0.000121	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—TGFB1—systemic scleroderma	1.26e-05	0.000121	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CCL2—systemic scleroderma	1.26e-05	0.00012	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—NOS3—systemic scleroderma	1.25e-05	0.00012	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—NOS3—systemic scleroderma	1.12e-05	0.000107	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—TGFB1—systemic scleroderma	1.11e-05	0.000106	CbGpPWpGaD
Gefitinib—EGFR—Disease—TGFB1—systemic scleroderma	1.06e-05	0.000101	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CTGF—systemic scleroderma	9.59e-06	9.17e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MMP9—systemic scleroderma	9e-06	8.61e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—NOS3—systemic scleroderma	8.98e-06	8.59e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—NOS3—systemic scleroderma	8.48e-06	8.11e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—NOS3—systemic scleroderma	7.73e-06	7.4e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TGFB1—systemic scleroderma	7.42e-06	7.1e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—NOS3—systemic scleroderma	6.94e-06	6.64e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—NOS3—systemic scleroderma	6.77e-06	6.48e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—NOS3—systemic scleroderma	6.38e-06	6.11e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—NOS3—systemic scleroderma	6.33e-06	6.05e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—NOS3—systemic scleroderma	4.17e-06	3.99e-05	CbGpPWpGaD
